Mean Systemic Filling Pressure and Heart Performance Predicting Fluid Responsiveness in Aortic Valve Replacement
Launched by CATHARINA ZIEKENHUIS EINDHOVEN · May 19, 2016
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
The assessment of the cardiovascular state in critically ill patients is subject to difficulties in terms of the fact that several hemodynamic parameters, for example mean arterial blood pressure (MAP) and cardiac output (CO) supply insufficient information about the circulating volume and cardiac performance. There is a clinical need to adequate determination of intravascular volume status and therefore reliable predictors of fluid responsiveness are highly relevant. However, in determining the fluid status of a patient, the lack of appreciation of the venous side of the circulation persis...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must be older than 18 years, and must be equipped with a pulse-contour cardiac output system with a central venous catheter.
- • Patients will be subsequently connected to the hemodynamic monitoring device Navigator™.
- • In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
- Exclusion Criteria:
- • Patients with assist devices (e.g. intra aortic balloon pump, Impella®, ECMO), patients with arrhythmias (either atrial of ventricular) will be excluded from the study.
- • Also, patients with inguinal impairment or contraindications for a passive leg raising will be excluded (such as deep venous thrombosis or elastic compression stocking), head trauma, an increase intra-abdominal pressure suspected by clinical context and examination as well as patients with absolute contraindications for fluid challenge.
About Catharina Ziekenhuis Eindhoven
Catharina Ziekenhuis Eindhoven is a leading healthcare institution in the Netherlands, dedicated to delivering high-quality patient care and advancing medical research. As a prominent clinical trial sponsor, the hospital is committed to facilitating innovative research initiatives that aim to improve treatment outcomes and enhance patient quality of life. With a diverse range of medical specialties and a collaborative approach, Catharina Ziekenhuis Eindhoven fosters an environment that supports rigorous clinical trials, ensuring adherence to ethical standards and regulatory guidelines while prioritizing patient safety and well-being. Through its robust infrastructure and expertise, the hospital actively contributes to the development of new therapies and medical technologies, playing a vital role in the evolution of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Eindhoven, North Brabant, Netherlands
Patients applied
Trial Officials
Jan Bakker, MD, PhD
Study Chair
Erasmus Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials